Original Article

You have full text access to this OnlineOpen article

Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-Induced neutropenia†

  1. Mark L. Heaney MD, PhD1,‡,*,
  2. Edmond L. Toy PhD2,
  3. Francis Vekeman MA3,
  4. François Laliberté MA3,
  5. Bree L. Dority PhD2,
  6. Daniel Perlman BA2,
  7. Victoria Barghout MSPH4,
  8. Mei Sheng Duh MPH, ScD5

Article first published online: 27 JUL 2009

DOI: 10.1002/cncr.24535

Issue

Cancer

Cancer

Volume 115, Issue 20, pages 4839–4848, 15 October 2009

Additional Information

How to Cite

Heaney, M. L., Toy, E. L., Vekeman, F., Laliberté, F., Dority, B. L., Perlman, D., Barghout, V. and Duh, M. S. (2009), Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-Induced neutropenia. Cancer, 115: 4839–4848. doi: 10.1002/cncr.24535

Author Information

  1. 1

    Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York

  2. 2

    Analysis Group, Inc, Lakewood, Colorado

  3. 3

    Analysis Group, Inc, Montreal, Quebec, Canada

  4. 4

    U.S. Health Economics and Outcomes Research Division, Bayer HealthCare Pharmaceuticals, Inc, Wayne, New Jersey

  5. 5

    Analysis Group, Inc, Boston, Massachusetts

  1. ‡

    Fax: (212) 772-8550

*Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065

  1. †

    Presented in part at the 50th Annual Meeting and Exposition of the American Society of Hematology, San Francisco, California, December 6-9, 2008.

Publication History

  1. Issue published online: 5 OCT 2009
  2. Article first published online: 27 JUL 2009
  3. Manuscript Accepted: 1 MAY 2009
  4. Manuscript Revised: 19 MAR 2009
  5. Manuscript Received: 22 DEC 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (158K)

References

  • 1
    Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004; 100: 228-237.
    Direct Link:
  • 2
    Lyman GH, Kuderer NM. Epidemiology of febrile neutropenia. Support Cancer Ther. 2003; 1: 23-35.
  • 3
    National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors, V. 1.2008. Available at: http://www.nccn.org/professionals/physician_gls/PDF/myeloid_growth.pdf Accessed May 12, 2008.
  • 4
    Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005; 103: 1916-1924.
    Direct Link:
  • 5
    Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006; 106: 2258-2266.
    Direct Link:
  • 6
    Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006; 24: 3187-3205.
  • 7
    Weber J, Sondak VK, Scotland R, et al. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer. 2003; 97: 186-200.
    Direct Link:
  • 8
    Slingluff CLJr, Petroni GR, Yamshchikov GV, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using 4 melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol. 2003; 21: 4016-4026.
  • 9
    Ruttinger D, van den Engel NK, Winter H, et al. Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response. J Transl Med. 2007; 5: 43.
  • 10
    Jones SE, Schottstaedt MW, Duncan LA, et al. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer. J Clin Oncol. 1996; 14: 2976-2983.
  • 11
    Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med. 2002; 112: 406-411.
  • 12
    Yau JC, Neidhart JA, Triozzi P, et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin. Am J Hematol. 1996; 51: 289-295.
    Direct Link:
  • 13
    Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer. 1993; 29A: 319-324.
  • 14
    Milkovich G, Moleski RJ, Reitan JF, et al. Comparative safety of filgrastim versus sargramostim in patients receiving myelosuppressive chemotherapy. Pharmacotherapy. 2000; 20: 1432-1440.
  • 15
    Wong SF, Chan HO. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy. Pharmacotherapy. 2005; 25: 372-378.
  • 16
    Beveridge RA, Miller JA, Kales AN, et al. Randomized trial comparing the tolerability of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in cancer patients receiving myelosuppressive chemotherapy. Support Care Cancer. 1997; 5: 289-298.
  • 17
    Beveridge RA, Miller JA, Kales AN, et al. A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression. Cancer Invest. 1998; 16: 366-373.
  • 18
    Stull DM, Bilmes R, Kim H, Fichtl R. Comparison of sargramostim and filgrastim in the treatment of chemotherapy-induced neutropenia. Am J Health Syst Pharm. 2005; 62: 83-87.
  • 19
    Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993; 46: 1075-109; discussion 1081-1090.
  • 20
    Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst. 1998; 90: 1205-1211.
  • 21
    Chrischelles EA, Link BK, Scott SD, Delgado DJ, Fridman M. Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate-grade non-Hodgkin's lymphoma. Cancer Control. 2003; 10: 396-403.
  • 22
    Dale DC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs. 2002; 62( suppl 1): 1-15.
  • 23
    Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007; 25: 3158-3167.
  • 24
    Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005; 23: 1178-1184.
  • 25
    Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood. 1995; 86: 457-462.
  • 26
    Nemunaitis J, Rabinowe SN, Singer JW, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med. 1991; 324: 1773-1778.
  • 27
    Nemunaitis J, Rosenfeld CS, Ash R, et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995; 15: 949-954.
  • 28
    Bennett C, Stinson T, Bhoopalam N, Marriott M, Panganiban J, Kozloff M. A double-blind, randomized trial of toxicity, resource use and costs for filgrastim and sargramostim [abstract]. Proc Am Soc Clin Oncol. 2000; 19: 437a. Abstract 1712.
  • 29
    Whalen CR, Watson TL, Baize T, Ball A. Formulary management of colony-stimulating factors. Am J Health Syst Pharm. 2002; 59( 7 suppl 2): S21-S27.
View Full Article (HTML) Get PDF (158K)